Concord Biotech Limited completes EUGMP inspection at its API facility

The European Union Good Manufacturing Practice (EU-GMP) authorities have conducted their first inspection of Concord Biotech Limited's Active Pharmaceutical Ingredients (API) manufacturing facility located at Limbassi. The inspection was carried out from August 18, 2025 to August 21, 2025.

This milestone marks a significant achievement for Concord, as a successful EU-GMP inspection not only validates our commitment to global quality standards but also paves the way for expanding our footprint into new international markets. The approval will enable Concord to explore commercial opportunities across various EU territories and other regulated geographies, strengthening our global presence and growth trajectory.

This milestone reaffirms our commitment to the highest standards of quality, safety, and regulatory compliance, reflecting our dedication to operational excellence and alignment with global regulatory expectations.

Shares of Concord Biotech Limited was last trading in BSE at Rs. 1692.90 as compared to the previous close of Rs. 1649.05. The total number of shares traded during the day was 3957 in over 609 trades.

The stock hit an intraday high of Rs. 1700.00 and intraday low of 1650.20. The net turnover during the day was Rs. 6657100.00.

Source : Equity Bulls

Keywords

ConcordBiotech Pharmaceuticals INE338H01029 EUGMP Inspection APIFacility Limbassi